Poland has appealed a Brussels court judgment ordering it to take delivery of about 64 million unwanted Covid-19 vaccine doses and pay Pfizer roughly €1.3 billion, escalating a dispute that has become a legal and political fight over a pandemic-era contract.
According to Politico EU, the Polish government also asked judges to freeze provisional enforcement of the ruling while the challenge is heard. Warsaw argued that the end of the pandemic and Russia's invasion of Ukraine had upended the original deal. The Health Ministry said the lower court's decision did not take into account all relevant factual and legal circumstances.
The case is large in both money and public-health scale. Roughly 64 million doses is far more than a single national backstop order. The amount at stake, about €1.3 billion, makes the dispute one of the most significant vaccine contract battles to surface from the pandemic period.
The reporting indicates that Poland is not merely contesting payment terms. It is arguing that the context in which the contract was negotiated has changed fundamentally. The war in Ukraine altered budgets, logistics and political priorities across Europe, while the pandemic itself moved from emergency footing into a more routine phase. Poland's appeal suggests it believes those shifts matter legally, not just politically.
The article does not give the full terms of the original contract, but it does show that the dispute has reached a point where Poland is seeking both appeal and suspension of enforcement. That matters because it means the government wants to prevent the ruling from being carried out while the courts continue to review the case.
The legal fight also reflects a broader question many governments faced after the acute phase of the pandemic: how to handle vaccines ordered in emergency conditions but no longer needed at the same scale. In this case, the answer has become a courtroom battle in Brussels.
For Poland, the outcome could determine not only whether it owes Pfizer the money, but also whether it must accept millions of doses it says it no longer wants. The government's challenge implies that it sees the judgment as too rigid for the circumstances. For Pfizer, the ruling represents a claim to payment on a contract it says should still stand.
At this stage, the supplied evidence does not report a final resolution. What it does show is a country trying to use the courts to redraw the terms of a deal that was shaped by a health emergency and then overtaken by the end of that emergency and the wider geopolitical shock of war in Europe.
